Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

AbbVie (ABBV) gains FDA approval for Juvmo, a first-in-class Parkinson's treatment launching October 2026. Stock dips 0.29% despite breakthrough.

The researchers found that the addictive-like effect of levodopa was due to its ability to hyperactivate a group of neurons expressing the dopamine D1 receptor (D1R) in the basal ganglia. The next ...

The FDA has required stronger warnings that medicines containing carbidopa and levodopa can deplete vitamin B6 and, in rare severe cases, contribute to seizures. The combination remains a cornerstone ...

An extended-release version of a Parkinson's disease drug could provide more stable relief for patients with the movement disorder, new clinical trial data show. The new formulation of levodopa, ...

The successful administration of levodopa in the treatment of Parkinson's disease in 1967 was nothing short of miraculous. 1 Early morning news shows of the time ran film clips of pre-treatment ...